Delayed 18F-fluorodeoxyglucose PET/CT imaging improves quantitation of atherosclerotic plaque inflammation: Results from the CAMONA study

详细信息    查看全文

• 作者：Bj?rn A. Blomberg MD ; MSc (1) (2)
  Anders Thomassen MD (1)
  Richard A. P. Takx MD ; MSc (2)
  Malene G. Hildebrandt MD ; PhD (1)
  Jane A. Simonsen MD (1)
  Karen M. Buch-Olsen MD (1)
  Axel C. P. Diederichsen MD ; PhD (3)
  Hans Mickley MD ; DMSc (3)
  Abass Alavi MD ; PhD ; DSc (4)
  Poul F. H?ilund-Carlsen MD ; DMSc (1)
  
• 关键词：PET/CT ; 18F ; fluorodeoxyglucose (18FDG) ; atherosclerosis ; vascular inflammation
• 刊名：Journal of Nuclear Cardiology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：21
• 期：3
• 页码：588-597
• 全文大小：
• 参考文献：1. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-d -glucose positron emission tomography. J Am Coll Cardiol 2011;58:603-14. CrossRef
  2. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11. CrossRef
  3. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multi-center FDG-PET/CT feasibility study. J Am Coll Cardiol 2013;62:909-17. CrossRef
  4. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31. CrossRef
  5. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009;50:1611-20. CrossRef
  6. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 2012;59:2080-8. CrossRef
  7. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008;49:871-8. CrossRef
  8. Kim TN, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: Analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging 2010;3:142-8. CrossRef
  9. Bucerius J, Duivenvoorden R, Mani V, Moncrieff C, Rudd JH, Calcagno C, et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging 2011;4:1195-205. CrossRef
  10. Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC, Cullum I, et al. Vascular inflammation imaging with 18F-FDG PET/CT: When to image? J Nucl Med 2009;50:854-7. CrossRef
  11. Blomberg BA, Akers SR, Saboury B, Mehta NN, Cheng G, Torigian DA, et al. Delayed time-point 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation. Nucl Med Commun 2013;34:860-7.
  12. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003. CrossRef
  13. Becker CR, Knez A, Ohnesorge B, Schoepf UJ, Flohr T, Bruening R, et al. Visualization and quantification of coronary calcifications with electron beam and spiral computed tomography. Eur Radiol 2000;10:629-35. CrossRef
  14. Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hrobjartsson A, et al. Guidelines for reporting reliability and agreement studies (GRRAS) were proposed. J Clin Epidemiol 2011;64:96-106. CrossRef
  15. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10. CrossRef
  16. Rudd JH, Elkhawad M, Fayad ZA. Vascular imaging with 18F-FDG PET/CT: Optimal 18F-FDG circulation time? J Nucl Med 2009;50:1560. CrossRef
  17. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-6. CrossRef
  18. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639-47. CrossRef
  19. Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med 2009;50:497-500. CrossRef
  20. Otsuka M, Bruining N, Van Pelt NC, Mollet NR, Ligthart JM, Vourvouri E, et al. Quantification of coronary plaque by 64-slice computed tomography: A comparison with quantitative intracoronary ultrasound. Invest Radiol 2008;43:314-21. CrossRef
  21. Sanchez-Crespo A, Andreo P, Larsson SA. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 2004;31:44-51. CrossRef
  22. Basu S, Zaidi H, Houseni M, Bural G, Udupa J, Acton P, et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: Implications for normal variation, aging and diseased states. Semin Nucl Med 2007;37:223-39. CrossRef
  
• 作者单位：Bj?rn A. Blomberg MD, MSc (1) (2)
  Anders Thomassen MD (1)
  Richard A. P. Takx MD, MSc (2)
  Malene G. Hildebrandt MD, PhD (1)
  Jane A. Simonsen MD (1)
  Karen M. Buch-Olsen MD (1)
  Axel C. P. Diederichsen MD, PhD (3)
  Hans Mickley MD, DMSc (3)
  Abass Alavi MD, PhD, DSc (4)
  Poul F. H?ilund-Carlsen MD, DMSc (1)
  
  1. Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense, Denmark
  2. Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
  3. Department of Cardiology, Odense University Hospital, Odense, Denmark
  4. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
  
• ISSN：1532-6551

文摘

Background This study aimed to determine if delayed 18F-fluorodeoxyglucose (18FDG) PET/CT imaging improves quantitation of atherosclerotic plaque inflammation. Blood-pool activity can disturb the arterial 18FDG signal. With time, blood-pool activity declines. Therefore, delayed imaging can potentially improve quantitation of vascular inflammation. Methods and Results 40 subjects were prospectively assessed by dual-time-point PET/CT imaging at approximately 90 and 180?minutes after 18FDG administration. For both time-points, global uptake of 18FDG was determined in the carotid arteries and thoracic aorta by calculating the blood-pool corrected maximum standardized uptake value (cSUVMAX). A target-to-background ratio (TBR) was calculated to determine the contrast resolution at 90 and 180?minutes. Furthermore, we assessed whether the acquisition time-point affected the relation between cSUVMAX and the estimated 10-year risk for fatal cardiovascular disease (SCORE %). A significant increase in carotid cSUVMAX (23%, P?<?.0001), carotid TBR (20%, P?<?.0001), aortic cSUVMAX (14%, P?<?.0001), and aortic TBR (20%, P?<?.0001) was observed with time. At 90?minutes, cSUVMAX did not relate to SCORE %, whereas at 180?minutes significant positive relations were observed between SCORE % and carotid (τ?=?0.25, P?=?.045) and aortic (τ?=?0.33, P?=?.008) cSUVMAX. Conclusions Delayed 18FDG PET/CT imaging at 180?minutes improves quantitation of atherosclerotic plaque inflammation over imaging at 90?minutes. Therefore, the optimal acquisition time-point to assess atherosclerotic plaque inflammation lies beyond the advocated time-point of 90?minutes after 18FDG administration.